4.5 Article

Multiplex assessment of SARS-CoV-2 antibodies improves assay sensitivity and correlation with neutralizing antibodies

Journal

CLINICAL BIOCHEMISTRY
Volume 97, Issue -, Pages 54-61

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2021.08.006

Keywords

SARS-CoV-2; COVID-19; Antibody; Serology; Neutralization assay

Funding

  1. Bio-Rad Laboratories
  2. DSF Charitable Foundation
  3. University of Pittsburgh Clinical and Translational Science Institute (CTSI)

Ask authors/readers for more resources

The study aimed to detect antibodies to different SARS-CoV-2 antigens, analyzing the performance of the BioRad SARS-CoV-2 IgG multiplex assay in terms of diagnostic accuracy, differentiation of vaccination and natural disease, and retrospective exposure determination. Results showed that the assay is comparable to existing methods, achieving 100% sensitivity when all markers are included, with practical implications for research and infection prevention strategies.
Objectives: Detection of antibodies to multiple SARS-CoV-2 antigens in a single assay could increase diagnostic accuracy, differentiate vaccination from natural disease, and aid in retrospective exposure determination. Correlation of binding antibody assessment in clinical assays with neutralizing antibodies is needed to better understand the humoral response to SARS-CoV-2 infection and establish of correlates of protection. Methods: A cohort of 752 samples was used to assess specificity, sensitivity, and comparison to 6 other Conformite Europeenne serologic assays for the BioRad SARS-CoV-2 IgG multiplex assay which measures receptor binding domain IgG (RBD), spike-S1 IgG (S1), spike-S2 IgG (S2), and nucleocapsid IgG (N). A subset of serial specimens from 14 patients was also tested for neutralizing antibodies (n = 61). Results: Specificity for RBD and S1 IgG was 99.4% (n = 170) and 100% for S2 and N IgG (n = 170) in a cohort selected for probable interference. Overall assay concordance with other assays was >93% for IgG and total antibody assays and reached 100% sensitivity for clinical concordance at >14 days as a multiplex assay. RBD and S1 binding antibody positivity demonstrated 79-95% agreement with the presence of neutralizing antibodies. Conclusions: The BioRad SARS-CoV-2 IgG assay is comparable to existing assays, and achieved 100% sensitivity when all markers were included. The ability to measure antibodies against spike and nucleocapsid proteins simultaneously may be advantageous for complex clinical presentations, epidemiologic research, and in decisions regarding infection prevention strategies. Additional independent validations are needed to further determine binding antibody and neutralizing antibody correlations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available